Mankind Pharma Takes a Hit as Lock-in Period Ends, 70% of Shares Eligible for Trading

Mankind Pharma, a prominent pharmaceutical company, witnessed a dip in its share price of about 2% as the lock-in period for shareholders came to an end on Monday. The stock value fell by as much as 2.40% to Rs 1,732.65 per share on the Bombay Stock Exchange (BSE), leaving investors on edge.

With the end of the lock-in period, approximately 70% of Mankind Pharma's outstanding shares are now eligible for trading, marking a significant turning point for the company's shareholders. According to data from Nuvama Alternative and Quantitative Research, more than 28 crore Mankind Pharma shares have become eligible for trading, as reported by market analysts.

As the stock market opened today, investors can anticipate a surge in trading volumes for Mankind Pharma shares, potentially leading to increased market volatility and fluctuations in share prices. It's a critical juncture for both existing shareholders and potential investors looking to enter the market.

Mankind Pharma made an impressive stock market debut on May 9, 2023, following a successful initial public offering (IPO) in which the company raised Rs 4,326.36 crore. The stock was listed at a substantial premium of 20%, trading at Rs 1,300 per share on the BSE, significantly higher than the IPO price of Rs 1,026 to Rs 1,080 per share.

Since its IPO, Mankind Pharma's share price has soared, posting remarkable gains. It has rallied more than 36% from its listing price and an impressive 64% from its IPO price, reflecting investors' confidence in the company's growth prospects and financial performance.

In the second quarter of the financial year 2023-24, Mankind Pharma reported a net profit of Rs 511 crore, registering a substantial growth of 21% from the previous year's Rs 422 crore in the corresponding quarter. The company's revenue during the same period increased by 11.6% year-on-year, reaching Rs 2,708 crore.

At the operational level, the earnings before interest, tax, depreciation, and amortization (EBITDA) also exhibited robust growth, surging by 15.4% year-on-year to Rs 686 crore. Furthermore, Mankind Pharma improved its EBITDA margin by 80 basis points (bps) year-on-year, reaching 25.3%, showcasing efficient financial management.

However, the September quarter presented some challenges for the pharmaceutical giant as it grappled with a slowdown in the acute segment sales. This slowdown had a dampening effect on domestic growth, even though the company managed to offset it with sustained momentum in the Chronic portfolio, price hikes, and increased exports, according to analysts.

As of noon on Monday, the Mankind Pharma stock was trading with cuts of nearly 2% at ₹1,741.20 per share on the National Stock Exchange (NSE). It remains to be seen how the market will respond to the increased availability of shares for trading as the lock-in period ends.

Mankind Pharma has certainly come a long way since its IPO, and as the pharmaceutical sector continues to evolve, investors will be watching closely to see how the company fares in the post-lock-in period environment.